Adaptive Biotechnologies

Adaptive Biotechnologies

Decodes immune cell genetic information for diagnostics

About

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand how the immune system reacts to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to leverage immune system data to advance healthcare and address various diseases.

Company Stage

IPO

Employees

501-1,000

Industries

Data & Analytics, Biotechnology, Healthcare

Total Funding

$395.8M

Headquarters

N/A

Founded

2009


Simplify Jobs

Simplify's Take

What believers are saying

  • Adaptive Biotechnologies' partnerships with pharmaceutical companies and healthcare providers offer significant growth opportunities and revenue streams.
  • Winning the Workplace of the Year Award highlights their strong company culture and employee satisfaction, making it an attractive place to work.
  • Their collaboration with BeiGene on minimal residual disease measurement could lead to groundbreaking advancements in cancer treatment.

What critics are saying

  • The departure of key board members like Kevin Conroy and Leslie Trigg could lead to strategic instability.
  • The highly competitive biotechnology sector requires continuous innovation to maintain market position.

What makes Adaptive Biotechnologies unique

  • Adaptive Biotechnologies leverages the genetic information of immune cell receptors to develop advanced diagnostic tools and treatments, setting it apart from traditional biotech firms.
  • Their ImmuneRACE study, focusing on COVID-19 immune response, showcases their commitment to addressing current global health challenges.
  • The integration of their clonoSEQ® assay with Epic systems enhances their diagnostic capabilities, providing a seamless experience for healthcare providers.

Help us improve and share your feedback! Did you find this helpful?


Growth & Insights
Headcount

6 month growth

-5%

1 year growth

-11%

2 year growth

-15%

Recently Posted Jobs

Sign up to get curated job recommendations

Adaptive Biotechnologies is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Adaptive Biotechnologies's jobs every 8 hours, so check again soon! Browse all jobs →